Literature DB >> 2113553

Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis.

P F Barnes1, S J Fong, P J Brennan, P E Twomey, A Mazumder, R L Modlin.   

Abstract

TNF and IFN-gamma are thought to be involved in the immune response to mycobacterial infection because they exhibit antimycobacterial effects in vitro. To investigate the roles of these cytokines in vivo at the site of disease activity in human tuberculosis, we evaluated local cytokine production in patients with tuberculous pleuritis. Both TNF and IFN-gamma were selectively concentrated 5- to 30-fold in pleural fluid, compared to blood of the same patients. Messenger RNA for both cytokines was detected in pleural tissue by in situ hybridization, suggesting that selective cytokine concentration is due to local cytokine production. Two Mycobacterium tuberculosis cell wall components, the protein-peptidoglycan complex and lipoarabinomannan, caused dose-dependent release of TNF by pleural fluid mononuclear cells and may constitute the stimuli for TNF production in the pleural space. In contrast to results obtained for TNF release, the protein-peptidoglycan complex, but not lipoarabinomannan, stimulated IFN-gamma release by pleural fluid mononuclear cells. The clinical manifestations of tuberculous pleuritis, such as fever, exudative pleural effusion, and tissue necrosis, may be due to the effects of elevated local TNF concentrations, produced in response to mycobacterial cell wall components.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113553

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  95 in total

1.  Generalized immunological decline during long-term experimental infection with Mycobacterium avium.

Authors:  Brad Gilbertson; Christina Cheers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor.

Authors:  D Chatterjee; A D Roberts; K Lowell; P J Brennan; I M Orme
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Production and characterization of guinea pig recombinant gamma interferon and its effect on macrophage activation.

Authors:  A Jeevan; C T McFarland; T Yoshimura; T Skwor; H Cho; T Lasco; D N McMurray
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 4.  Production of inflammatory cytokines in the intestinal lamina propria.

Authors:  C Fiocchi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 6.  Potential role of cytokines in disseminated mycobacterial infections.

Authors:  L E Bermudez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

7.  Regulation of the interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs.

Authors:  Y Zhang; W N Rom
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

8.  Pleural fluid interferon-gamma and adenosine deaminase levels in tuberculosis pleural effusion: a cost-effectiveness analysis.

Authors:  S K Sharma; Amit Banga
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

9.  Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines.

Authors:  Ferah Budak; Esra Kunt Uzaslan; Sengül Cangür; Güher Göral; Haluk Barbaros Oral
Journal:  Lung       Date:  2008-07-29       Impact factor: 2.584

10.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.